Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

Pallas Capital Advisors jumped into the biotech game by purchasing $426,000 worth of Regeneron Pharmaceuticals shares during ...

The S&P 500 rebounded in May, but some stocks crashed on company-specific concerns. While one healthcare giant withdrew its ...

The co-founder of bankrupt genetic analysis company 23andMe won an auction for the firm’s assets, agreeing, along with a ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Atwood & Palmer Inc. slightly reduced its stake in Regeneron Pharmaceuticals, selling 1,709 shares in Q1 while still holding ...

IQVIA stock may look ready for a breakout, but Adhishthana analysis reveals a complex time spiral that could last until 2030.

A significant trading signal occurred for Regeneron Pharma stock at a price of $501.83, after which REGN rose up to 3.2%.